Avalyn Pharma Inc. Common Stock (AVLN) — Working Capital to Net Assets Ratio
Avalyn Pharma Inc. Common Stock (AVLN) has a Working Capital to Net Assets ratio of -54.2% as of December 2025. Working capital of $129.47 Million (current assets of $143.56 Million minus current liabilities of $14.09 Million) is measured against net assets of $-238.66 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Avalyn Pharma Inc. Common Stock (AVLN) balance sheet quality index to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Avalyn Pharma Inc. Common Stock Working Capital to Net Assets (2024–2025)
This chart shows how Avalyn Pharma Inc. Common Stock's Working Capital to Net Assets ratio has evolved across 2 annual periods from 2024 to 2025. As of December 2025, the ratio stands at -54.2%, reflecting working capital of $129.47 Million against net assets of $-238.66 Million USD. See Avalyn Pharma Inc. Common Stock liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Avalyn Pharma Inc. Common Stock (2024–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Avalyn Pharma Inc. Common Stock from 2024 to 2025, covering 2 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see AVLN market cap.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -54.2% | $129.47 Million | $-238.66 Million | $143.56 Million | $14.09 Million | ▲ +6.3 pp |
| 2024 | -60.5% | $105.64 Million | $-174.52 Million | $114.39 Million | $8.74 Million | — |